XOMA Corporation

NasdaqGM XOMA

XOMA Corporation Price to Sales Ratio (P/S) on January 14, 2025: 14.57

XOMA Corporation Price to Sales Ratio (P/S) is 14.57 on January 14, 2025, a -69.61% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

XOMA Corporation 52-week high Price to Sales Ratio (P/S) is 63.87 on March 15, 2024, which is 338.48% above the current Price to Sales Ratio (P/S).
XOMA Corporation 52-week low Price to Sales Ratio (P/S) is 13.69 on December 19, 2024, which is -5.99% below the current Price to Sales Ratio (P/S).
XOMA Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 33.72.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: XOMA

XOMA Corporation

CEO	Mr. Owen P. Hughes Jr.
IPO Date	June 6, 1986
Location	United States
Headquarters	2200 Powell Street
Employees	13
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Key trends

Past 5 years